Lehtola J, Niemelä S, Martikainen J, Krekelä I
Scand J Gastroenterol. 1986 Mar;21(2):175-80. doi: 10.3109/00365528609034643.
The effect of ranitidine, 150 mg three times a day, in the treatment of reflux oesophagitis was studied. A double-blind method was used, and 41 patients with endoscopically verified symptomatic oesophagitis were randomly allocated to ranitidine or placebo. In addition, antacid tablets could be taken as needed. Eighteen patients in both the ranitidine and the placebo groups completed the study. Endoscopically, the healing rate was significantly higher in the ranitidine group after both 6 weeks' (p less than 0.05) and 12 weeks' (p less than 0.01) treatment. The proportion of patients whose oesophagitis healed or improved was also higher in the ranitidine group (p less than 0.05). The patients receiving ranitidine used significantly (p less than 0.002) less antacids than the controls, suggesting a favourable effect of ranitidine on the symptoms of oesophagitis. The histological study did not show significant differences between the ranitidine and the placebo groups. No serious side effects were noted. Ranitidine in a dose of 150 mg three times a day is effective and safe in the treatment of reflux oesophagitis.
研究了雷尼替丁（每日三次，每次150毫克）治疗反流性食管炎的效果。采用双盲法，将41例经内镜检查证实有症状的食管炎患者随机分为雷尼替丁组或安慰剂组。此外，可根据需要服用抗酸片。雷尼替丁组和安慰剂组各有18例患者完成了研究。内镜检查显示，治疗6周后（p<0.05）和12周后（p<0.01），雷尼替丁组的愈合率显著更高。雷尼替丁组食管炎愈合或改善的患者比例也更高（p<0.05）。接受雷尼替丁治疗的患者使用抗酸剂的量明显少于对照组（p<0.002），提示雷尼替丁对食管炎症状有良好疗效。组织学研究显示雷尼替丁组和安慰剂组之间无显著差异。未观察到严重副作用。每日三次，每次150毫克的雷尼替丁治疗反流性食管炎有效且安全。
